EBS | Emergent BioSolutions Inc. Stock Overview

(Stock Exchange: NYSE)

Day's Range	4.54 - 4.94
52 Week Range	1.8200 - 15.10
Beta	2.77
Implied Volatility	130.48%
IV Rank	26.95%
Day's Volume	1,313,694
Average Volume	1,176,851
Shares Outstanding	54,337,000
Market Cap	253,210,420
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2006-11-15

Valuation
Profitability
Growth
Health
P/E Ratio	-1.29
Forward P/E Ratio	-32.98
EPS	-3.60
1YR Price Target	37.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	2016-08-01
Dividend PayDate	N/A
Employees	1,600
Country	USA
Website	EBS

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

EBS's peers: BHC, DVAX, ZTS, PETQ, NBIX, AKAN, LFCR, PBH, ITCI, IZQVF, ALKS, CPIX, DCPH, COLL, DRRX, TAK, VTRS, HLN

*Chart delayed

Analyzing fundamentals for EBS we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is unacceptably poor, Growth is on medium level and Health is weak. For more detailed analysis please see EBS Fundamentals page.

Watching at EBS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EBS Technicals page.